From the *Center for Education and Research on Therapeutics (CERTs) and Departments of †Medicine, ‡Biostatistics, and §Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama; and ¶Department of Medicine, Duke University, Durham, North Carolina.
This project was funded by a Pharma Foundation Research Grant in Health Outcomes and Novartis Pharmaceuticals. Some of the investigators (J.R.C., K.G.S.) also receive support from the National Institutes of Health (AR053351, AR052361) and the Arthritis Foundation (J.R.C.). The authors independently developed the analysis plan, extracted the data, conducted the analysis, and interpreted the results.
Disclosures: J.W.C.—consulting: Roche; speakers bureau: Merck, Procter and Gamble, Eli Lilly, Roche. K.L.—consulting: Novartis, Procter & Gamble, Merck, Amgen, GTx, Lilly, GSK, and Bone Medical Ltd.; patent: US patent investor; “methods for preventing or reducing secondary fractures after hip fracture,” US patent application 20050272707; provisional patent application: “medication kits and formulations for preventing, treating, or reducing secondary fractures after previous fracture.” K.G.S.—consulting or speaking: Merck, Proctor and Gamble, Eli Lilly, Roche, Novartis, Amgen.
Reprints: Jeffrey R. Curtis, MD, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, UAB FOT 840, 510 20th Street South, Birmingham, AL 35294. E-mail: [email protected].